Healthcare
Eight Roads hires new India venture partner
Eight Roads, an independent investment firm backed by Fidelity International, has appointed pharmaceutical industry veteran Shirish Belapure as a venture partner in its India office.
Indian cardiac analytics firm Tricog raises $10.5m
Tricog, an India-based cardiac analytics firm, has raised $10.5 million in Series B funding from a group of domestic and international VCs.
Chinese insurance tech player raises $14m Series A
Chinese health insurance platform Nuanwa Technology has raised a RMB100 million ($14 million) Series A round led by Longfor Capital, a unit of real estate developer Longfor Group.
China's CBC raises healthcare credit fund
CBC Group, a China-focused healthcare investor, has raised a $300 million credit fund that will issue financing to companies backed by royalties, revenue interests, and other cash flows.
Sequoia, MassMutual back Indian medical imaging player
Qure, an India-based artificial intelligence-enabled medical imaging start-up, has raised $16 million in a Series A round led by Sequoia Capital India and MassMutual Ventures Southeast Asia.
Partners Group targets $1.4b buyout of Australia's Healius
Partners Group has been granted a call option on Chinese conglomerate Jangho Group’s 15.9% stake in Australian healthcare services provider Healius, enabling the private equity firm to make a A$2.1 billion ($1.4 billion) bid for the entire business.
First responders: China VCs on a healthcare crisis
The coronavirus outbreak has thrust Chinese healthcare services into the spotlight, prompting investors to identify to sub-segments with potential for significant growth
General Atlantic leads round for China's CANbridge Pharma
General Atlantic and WuXi AppTec, China’s leading contract research organization (CRO) WuXi AppTec, have led a $98 million Series D round for local drug developer CANbridge Pharmaceuticals.
HighLight hits $300m first close on China healthcare fund
Chinese healthcare-focused GP HighLight Capital has reached the first close of $300 million on its third US dollar-denominated fund, but further progress is likely to be delayed by the coronavirus outbreak.
CICC raises $229m for China healthcare fund
China's CICC Capital has raised RMB1.6 billion ($229 million) for its first fund dedicated to the biopharmaceutical space.
Rise Fund buys Bangladesh hospital operator
Evercare, a South Asia and Africa-focused healthcare delivery platform controlled by The Rise Fund, TPG Capital’s impact investment unit, has acquired Bangladesh-based Apollo Hospitals Dhaka.
Portfolio: Unison Capital and CHCP
Through its Community Healthcare Coordination Platform, Unison Capital wants to bring efficiencies and economies of scale to parts of Japan’s healthcare sector that have been isolated from private markets
Hamilton Lane backs Legend Capital fund restructuring
Hamilton Lane has led a $200 million restructuring of a VC fund managed by China-based Legend Capital, transferring 12 investments into a new vehicle as a means of extending the holding period.
Chinese medical imaging business secures $86m Series B
Shanghai-based Universal Medical Imaging, China’s largest independent imaging diagnosis company has raised a RMB600 million ($86 million) Series B round led by Cathay Capital, V Star Capital and CEC Capital.
Polaris pursues take-private of Japan's Sogo Medical
Polaris Capital Group has made an offer to privatize Sogo Medical Holdings, a Japanese pharmacy chain operator and B2B healthcare management platform, at a valuation of JPY76.3 billion ($694 million).
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
India’s Ascent invests in women’s pharma producer
Indian private equity firm Ascent Capital has invested INR1.25 billion ($17.5 million) in Naari Pharma, a women's health pharmaceutical business focused on hormonal generics.
AVCJ Awards 2019: Deal of the Year - Small Cap: AffaMed Therapeutics
CBC Group established biosimilars specialist AffaMed Therapeutics to remove uncertainties in the development process and to tap Chinese demand for affordable treatments
Chinese genetic testing player for infectious diseases gets Series B+
Chinese genetic testing specialist Genskey raised an RMB50 million ($7.1m) extended Series B round of funding led by Shenzhen-based Fortune Capital. Existing investor Legend Capital re-upped.
True North buys another unit from India's Glenmark
Mumbai-based Glenmark Pharmaceuticals has agreed to sell its gynecology operations in India and Nepal to a True North portfolio company for $16.2 million.
Green Pine leads Series B for Chinese gene testing player
Chinese gene testing business AmCare Genomics Lab has raised RMB110 million ($16 m) in Series B funding led by Green Pine Capital Partners. This comes four months after the company closed an extended Series A round of RMB30 million.
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
Ankur achieves first close on second India VC fund
Ankur Capital, an Indian early-stage investor focused on healthcare and agriculture technology investments, has reached a first close of INR2.4 billion ($33 million) on its second fund.